Home Cart Sign in  
Chemical Structure| 1346623-17-3 Chemical Structure| 1346623-17-3

Structure of Avacopan
CAS No.: 1346623-17-3

Chemical Structure| 1346623-17-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Avacopan is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.

Synonyms: CCX168

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Avacopan

CAS No. :1346623-17-3
Formula : C33H35F4N3O2
M.W : 581.64
SMILES Code : O=C([C@@H]1[C@H](C2=CC=C(NC3CCCC3)C=C2)N(C(C4=C(C)C=CC=C4F)=O)CCC1)NC5=CC=C(C)C(C(F)(F)F)=C5
Synonyms :
CCX168
MDL No. :MFCD28502293
InChI Key :PUKBOVABABRILL-YZNIXAGQSA-N
Pubchem ID :49841217

Safety of Avacopan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02384317 Immunoglobulin A Nephropathy PHASE2 COMPLETED 2018-06-01 Palo Alto, California, United ... More >>States|San Francisco, California, United States|Reno, Nevada, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|Stockholm, Sweden Less <<
NCT06758271 Microscopic Polyangiitis (MPA)... More >>|Granulomatosis With Polyangiitis (GPA) Less << RECRUITING 2028-05-31 Research site, Multiple Locati... More >>ons, Japan Less <<
NCT05988021 Anti-neutrophil Cytoplasmic An... More >>tibody-associated Vasculitis Less << PHASE1 COMPLETED 2016-05-25 Celerion, Tempe, Arizona, 8528... More >>3, United States Less <<
NCT06468826 End-Stage Renal Disease (ESRD) PHASE1 COMPLETED 2024-10-05 Floridian Clinical Research, L... More >>LC, Miami Lakes, Florida, 33016, United States|Orlando Clinical Research Center, Orlando, Florida, 32809-3017, United States Less <<
NCT06321601 Vasculitis PHASE3 RECRUITING 2030-07-20 Riley Hospital for Children, I... More >>ndianapolis, Indiana, 46202, United States|Cohen Children Medical Center, Lake Success, New York, 11042, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Akron Childrens Hospital, Akron, Ohio, 44308, United States|Upmc Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15224, United States|Texas Childrens Hospital, Houston, Texas, 77030, United States Less <<
NCT06004934 Hepatic Impairment PHASE1 COMPLETED 2018-09-18 Clinical Pharmacology of Miami... More >>, Inc., Hialeah, Florida, 33014, United States Less <<
NCT02464891 Atypical Hemolytic Uremic Synd... More >>rome Less << PHASE2 TERMINATED 2017-07-13 A.O. Papa Giovanni XXIII - U.O... More >>. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Bergamo, Italy Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.60mL

1.72mL

0.86mL

17.19mL

3.44mL

1.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records